ArticleFrontiers in public health2026
Thalassemia in Guangxi: current situation and future prospects.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guangxi, one of the regions with the highest thalassemia burden worldwide, has a carrier rate of 23.89% in the general population. Over the past 15 years, it has established a government-led, multi-sectoral prevention network based on the principles of "government leadership, multi-department coordination, healthcare sector accountability, integration of medical and preventive services, and public participation." This system has created an integrated "prevention-diagnosis-intervention-management" continuum supported by genetic testing and stem cell transplantation. Therefore, from 2010 to 2024, the birth rate of severe thalassemia decreased by 96.46%, and remained below 0.3 cases per 10,000 newborns for six consecutive years. This marks Guangxi's successful transformation from a high-incidence area to a national demonstration zone. The success of the Guangxi Model stems from a paradigm shift from reactive clinical treatment to proactive public health strategy, deep integration of public health with clinical practice, and continuous technological and systemic innovation. Guangxi's experience demonstrates that even in resource-limited settings, a systematic, multi-tiered strategy can effectively control genetic disorders, offering valuable lessons and a context-dependent reference for high-burden regions worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.